Shield Therapeutics has announced that its partner in Japan, MEDLEAP Pharma (Vital KSK), has commenced a Phase II clinical trial for ACCRUFeR®, as a new drug candidate for pulmonary arterial hypertension (PAH). This opens a new front for the development of ACCRUFeR, potentially paving the way towards a future Phase III pivotal study, and comes only seven months after the companies signed an exclusive licence agreement, which triggered an upfront payment to Shield and will allow Shield to receive ....
